Moderna, Inc. Basic Shares Outstanding (Weighted Average)
Moderna, Inc. (MRNA) reported Basic Shares Outstanding (Weighted Average) of 398.00 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-07-31
- Moderna, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 398.00M shares, a 2.58% increase year-over-year.
- Moderna, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 395.00M shares, a 2.33% increase year-over-year.
- Moderna, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 392.00M shares, a 1.29% increase year-over-year.
- Moderna, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 390.00M shares, a 1.30% increase year-over-year.
- Moderna, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 389.00M shares, a 1.30% increase from fiscal 2024.
- Moderna, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 384.00M shares, a 0.52% increase from fiscal 2023.
- Moderna, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 382.00M shares, a 3.05% decline from fiscal 2022.
- Moderna, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 394.00M shares, a 2.23% decline from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 398.00M shares 10-Q · filed 2026-07-31 | 396.00M shares 10-Q · filed 2026-07-31 | 395.00M shares derived: average of 3 quarters · filed 2026-07-31 | 393.75M shares derived: average of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | 395.00M shares 10-Q · filed 2026-05-01 | 393.50M shares derived: average of 2 quarters · filed 2026-05-01 | 392.33M shares derived: average of 3 quarters · filed 2026-05-01 | 391.25M shares derived: average of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | 392.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | 391.00M shares derived: average of 2 quarters · filed 2026-02-20 | 390.00M shares derived: average of 3 quarters · filed 2026-07-31 | 389.00M shares 10-K · filed 2026-02-20 |
| 2025-09-30 | 390.00M shares 10-Q · filed 2025-11-06 | 389.00M shares derived: average of 2 quarters · filed 2026-07-31 | 388.00M shares 10-Q · filed 2025-11-06 | 387.75M shares derived: average of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | 388.00M shares 10-Q · filed 2026-07-31 | 387.00M shares 10-Q · filed 2026-07-31 | 387.00M shares derived: average of 3 quarters · filed 2026-07-31 | 386.50M shares derived: average of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | 386.00M shares 10-Q · filed 2026-05-01 | 386.50M shares derived: average of 2 quarters · filed 2026-05-01 | 386.00M shares derived: average of 3 quarters · filed 2026-05-01 | 385.50M shares derived: average of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | 387.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | 386.00M shares derived: average of 2 quarters · filed 2026-02-20 | 385.33M shares derived: average of 3 quarters · filed 2026-02-20 | 384.00M shares 10-K · filed 2026-02-20 |
| 2024-09-30 | 385.00M shares 10-Q · filed 2025-11-06 | 384.50M shares derived: average of 2 quarters · filed 2025-11-06 | 383.00M shares 10-Q · filed 2025-11-06 | 383.25M shares derived: average of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | 384.00M shares 10-Q · filed 2025-08-01 | 383.00M shares 10-Q · filed 2025-08-01 | 382.67M shares derived: average of 3 quarters · filed 2026-02-20 | 382.25M shares derived: average of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | 382.00M shares 10-Q · filed 2025-05-01 | 382.00M shares derived: average of 2 quarters · filed 2026-02-20 | 381.67M shares derived: average of 3 quarters · filed 2026-02-20 | 381.50M shares derived: average of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | 382.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | 381.50M shares derived: average of 2 quarters · filed 2026-02-20 | 381.33M shares derived: average of 3 quarters · filed 2026-02-20 | 382.00M shares 10-K · filed 2026-02-20 |
| 2023-09-30 | 381.00M shares 10-Q · filed 2024-11-07 | 381.00M shares derived: average of 2 quarters · filed 2024-11-07 | 382.00M shares 10-Q · filed 2024-11-07 | 384.00M shares derived: average of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | 381.00M shares 10-Q · filed 2024-08-01 | 383.00M shares 10-Q · filed 2024-08-01 | 385.00M shares derived: average of 3 quarters · filed 2025-02-21 | 386.25M shares derived: average of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | 386.00M shares 10-Q · filed 2024-05-02 | 387.00M shares derived: average of 2 quarters · filed 2025-02-21 | 388.00M shares derived: average of 3 quarters · filed 2025-02-21 | 390.00M shares derived: average of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | 388.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | 389.00M shares derived: average of 2 quarters · filed 2025-02-21 | 391.33M shares derived: average of 3 quarters · filed 2025-02-21 | 394.00M shares 10-K · filed 2025-02-21 |
| 2022-09-30 | 390.00M shares 10-Q · filed 2023-11-03 | 393.00M shares derived: average of 2 quarters · filed 2023-11-03 | 396.00M shares 10-Q · filed 2023-11-03 | 398.50M shares derived: average of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | 396.00M shares 10-Q · filed 2023-08-03 | 399.00M shares 10-Q · filed 2023-08-03 | 401.33M shares derived: average of 3 quarters · filed 2024-02-23 | 402.00M shares derived: average of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | 402.00M shares 10-Q · filed 2023-05-04 | 404.00M shares derived: average of 2 quarters · filed 2024-02-23 | 404.00M shares derived: average of 3 quarters · filed 2024-02-23 | 403.50M shares derived: average of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | 406.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | 405.00M shares derived: average of 2 quarters · filed 2024-02-23 | 404.00M shares derived: average of 3 quarters · filed 2024-02-23 | 403.00M shares 10-K · filed 2024-02-23 |
| 2021-09-30 | 404.00M shares 10-Q · filed 2022-11-03 | 403.00M shares derived: average of 2 quarters · filed 2022-11-03 | 402.00M shares 10-Q · filed 2022-11-03 | 400.50M shares derived: average of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | 402.00M shares 10-Q · filed 2022-08-03 | 401.00M shares 10-Q · filed 2022-08-03 | 399.33M shares derived: average of 3 quarters · filed 2023-02-24 | 398.25M shares derived: average of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | 400.00M shares 10-Q · filed 2022-05-04 | 398.00M shares derived: average of 2 quarters · filed 2023-02-24 | 397.00M shares derived: average of 3 quarters · filed 2023-02-24 | 393.00M shares derived: average of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | 396.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | 395.50M shares derived: average of 2 quarters · filed 2023-02-24 | 390.67M shares derived: average of 3 quarters · filed 2023-02-24 | 381.00M shares 10-K · filed 2023-02-24 |
| 2020-09-30 | 395.00M shares 10-Q · filed 2021-11-04 | 388.00M shares derived: average of 2 quarters · filed 2021-11-04 | 376.00M shares 10-Q · filed 2021-11-04 | |
| 2020-06-30 | 381.00M shares 10-Q · filed 2021-08-05 | 367.00M shares 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | 353.00M shares 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 331.00M shares 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |